MRI for breast cancer screening

Annals of Oncology

Volumn 17, Issue SUPPL. 10, 2006, Pages

  Leach, M O ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN;

ARTICLE; BREAST BIOPSY; BREAST CANCER; BREAST TUMOR; CANCER RISK; CANCER SCREENING; CLINICAL EXAMINATION; CLINICAL TRIAL; CONTRAST ENHANCEMENT; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DIFFERENTIAL DIAGNOSIS; ECHOMAMMOGRAPHY; FALSE POSITIVE RESULT; FOLLOW UP; GENE MUTATION; GENETIC CODE; GENETIC SCREENING; HEALTH PROGRAM; HETEROZYGOTE; HIGH RISK PATIENT; HUMAN; IMAGE PROCESSING; IMAGE QUALITY; INTERMETHOD COMPARISON; MAMMOGRAPHY; MUTATIONAL ANALYSIS; NATIONAL HEALTH SERVICE; NUCLEAR MAGNETIC RESONANCE IMAGING; PAGET NIPPLE DISEASE; PATIENT SATISFACTION; POPULATION RESEARCH; PRIORITY JOURNAL; RADIOSENSITIVITY; SENSITIVITY AND SPECIFICITY; THREE DIMENSIONAL IMAGING; UNITED KINGDOM;

EID: 33749642638     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdl281     Document Type: Article

References (52)

1. Claus EB, Schildkraut JM, Thompson WD, Rich NJ. The genetic attributable risk of breast and ovarian cancer. Cancer 1996; 77: 2318-2324.
2. Claus EB. The genetic epidemiology of cancer. Cancer Surv 1995; 25: 13-26.
3. Malkin D, Li FP, Strong LC et al. Germ line P53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science 1990; 250: 1233-1238.
4. Eeles RA. Germline mutations in the TP53 gene. Cancer Surv 1995; 25: 101-124.
5. Hall JM, Lee MK, Newman B et al. Linkage of early-onset familial breast cancer to chromosome 17q21. Science 1990; 250: 1684-1689.
6. Easton DF, Bishop DT, Ford D, Crockford GP. Genetic linkage analysis in familial breast and ovarian cancer: Results from 214 families. The Breast Cancer Linkage Consortium. Am J Hum Genet 1993; 52: 678-701.
7. Wooster R, Neuhausen SL, Mangion J et al. Localization of a breast cancer susceptibility gene, BRCA2, to chromosome 13q12-13. Science 1994; 265: 2088-2090.
8. Wooster R, Bignell G, Lancaster J et al. Identification of the breast cancer susceptibility gene BRCA2. Nature 1995; 378: 789-792.
9. Lakhani SR, O'Hare MJ, Ashworth A. Profiling familial breast cancer. Nat Med 2001; 7: 408-410.
10. Lakhani SR, Gusterson BA, Jacquemier J et al. The pathology of familial breast cancer: Histological features of cancers in families not attributable to mutations in BRCA1 or BRCA2. Clin Cancer Res 2000; 6: 782-789.
11. Lakhani SR, Jacquemier J, Sloane JP et al. Multifactorial analysis of differences between sporadic breast cancers and cancers involving BRCA1 and BRCA2 mutations. J Natl Cancer Inst 1998; 90: 1138-1145.
12. Antoniou A, Pharoah PD, Narod S et al. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in rase series unselected for family history: A combined analysis of 22 studies. Am J Hum Genet 2003; 72: 1117-1130.
13. Narod SA, Offit K. Prevention and management of hereditary breast cancer. J Clin Oncol 2005; 23: 1656-1663.
14. Rebbeck TR, Friebel T, Lynch HT et al. Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: The PROSE Study Group. J Clin Oncol 2004; 22: 1055-1062.
15. Kerlikowske K, Barclay J. Outcomes of modern screening mammography. J Natl Cancer Inst Monogr 1997; 105-111.
16. Heywang SH, Hahn D, Schmidt H et al. MR Imaging of the breast using gadolinium-DTPA. J Comput Assist Tomogr 1986; 10: 199-204.
17. Heywang SH, Wolf A, Pruss E et al. MR imaging of the breast with Gd-DTPA: Use and limitations. Radiology 1989; 171: 95-103.
18. Heywang-Kobrunner SH, Bick U, Bradley WG Jr et al. International investigation of breast MRI: Results of a multicentre study (11 sites) concerning diagnostic parameters for contrast-enhanced MRI based on 519 histopathologically correlated lesions. Eur Radiol 2001; 11: 531-546.
19. Kaiser W, Zeitler E. [Nuclear magnetic resonance tomography of the breast: Diagnosis, differential diagnosis, problems and possible solutions. II: Diagnosis]. Rofo 1986; 144: 572-579.
20. Kalser WA. False-positive results in dynamic MR mammography. Causes, frequency, and methods to avoid. Magn Reson Imaging Clin N Am 1994; 2: 539-555.
21. Gilles R, Guinebretiere JM, Toussaint C et al. Locally advanced breast cancer: Contrast-enhanced subtraction MR imaging of response to preoperative chemotherapy. Radiology 1994; 191: 633-638,
22. Harms SE, Flamig DP, Hesley KL et al. MR Imaging of the breast with rotating delivery of excitation off resonance: Clinical experience with pathologic correlation. Radiology 1993; 187: 493-501.
23. Fischer U, von Heyden D, Vosshenrich R et al. Signal characteristics of malignant and benign lesions in dynamic 2D-MRT of the breast. Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr 1993; 158: 287-292.
24. Boetes C, Barentsz A Mus RD et al. MR characterization of suspicious breast lesions with a gadolinium-enhanced TurboFLASH subtraction technique. Radiology 1994; 193: 777-781.
25. Liu PF, Debatin JF, Caduff RF et al. Improved diagnostic accuracy in dynamic contrast enhanced MRI of the breast by combined quantitative and qualitative analysis. Br J Radiol 1998; 71: 501-509.
26. Perman WH, Heiberg EV, Herrmann VM. Half-Fourier, Three-dimensional technique for dynamic contrast-enhanced MR imaging of both breasts and axillae: Initial characterization of breast lesions. Radiology 1996; 200: 263-269.
27. Sardanelli F, Giuseppetti GM, Panizza P et al. Sensitivity of MRI versus mammography for detecting foci of multifocal, multicentric breast cancer in fatty and dense breasts using the whole-breast pathologic examination as a gold standard. Am J Roentgenol 2004; 183: 1149-1157.
28. Kuhl CK, Mielcareck P, Klaschik S et al. Dynamic breast MR imaging: Are signal intensity time course data useful for differential diagnosis of enhancing lesions? Radiology 1999; 211: 101-110.
29. Kriege M, Brekelmans CT, Boetes C et al. Efficacy of MRI and mammography for breast-cancer screening in women with a familial or genetic predispositon, N Engl J Med 2004; 351: 427-437.
30. Warner E, Plewes DB, Hill KA et al. Surveillance of BRCA1 and BRCA2 mutation carriers with magnetic resonance imaging, ultrasound, mammography, and clinical breast examination. J Am Med Assoc 2004; 292: 1317-1325.
31. Leach MO, Boggis CR, Dixon AK et al. Screening with magnetic resonance imaging and mammography of a UK population at high familial risk of breast cancer: A prospective multicentre cohort study (MARIBS). Lancet 2005; 365: 1769-1778.
32. Tilanus-Linthorst MM, Bartels CC, Obdeijn AI, Oudkerk M. Earlier detection of breast cancer by surveillance of women at familial risk. Eur J Cancer 2000: 36: 514-519.
33. Tilanus-Linthorst MM, Obdeijn IM, Bartels KC et al. First experiences in screening women at high risk for breast cancer with MR imaging. Breast Cancer Res Treat 2000; 63: 53-60.
34. Boetes C, Stoutjesdljk M. MR imaging in screening women at increased risk for breast cancer. Magn Reson Imaging Clin N Am 2001; 9: 357-372.
35. Stoutjesdljk MJ, Boetes C, Jager GJ et al. Magnetic resonance imaging and mammography in women with a hereditary risk of breast cancer. J Natl Cancer Inst 2001; 93: 1095-1102.
36. Kuhl CK, Schmutzler RK, Leutner CC et al. Breast MR imaging screening in 192 women proved or suspected to be carriers of a breast cancer susceptibility gene: Preliminary results. Radiology 2000: 215: 267-279.
37. Kuhl CK. High-risk screening: Multi-modality surveillance af women at high risk for breast cancer (proven or suspected carriers of a breast cancer susceptibility gene). J Exp Clin Cancer Res 2002; 21: 103-106.
38. Podo F, Sardanelli F, Canese R et al. The Italian multi-centre project on evaluation of MRI and other imaging modalities in early detection of breast cancer in subjects at high genetic risk. J Exp Clin Cancer Res 2002; 21: 115-124.
39. Morris EA, Liberman L, Ballon DJ et al. MRI of occult breast carcinoma in a high-risk population. Am J Roentgenol 2003; 181: 619-626.
40. Leach MO, Eeles RA, Turnbull LW et al. The UK national study of magnetic resonance imaging as a method at screening for breast cancer (MARIBS). J Exp Clin Cancer Res 2002; 21: 107-114.
41. Warren RM, Pointon L, Caines R et al. What is the recall rate of breast MRI when used for screening asymptomatic women at high risk? Magn Reson Imaging 2002; 20: 557-565.
42. Degenhard A, Tanner C, Hayes C et al. Comparison between radiological and artificial neural network diagnosis in clinical screening. Physiol Meas 2002; 23: 727-739.
43. Lehman CO, Schnall MD, Kuhl CK, Harms SE. Report of the working groups on breast MRI: Report of the high-risk screening group. Breast J 2004; 10 (Suppl 2): S9-S12.
44. Brown J, Coulthard A, Dixon AK et al. Rationale for a national multi-centre study of magnetic resonance imaging screening in women at genetic risk of breast cancer. Breast 2000; 9: 72-77.
45. Brown J, Coulthard A, Dixon AK et al. Protocol for a national multi-centre study of magnetic resonance imaging screening in women at genetic risk of breast cancer. Breast 2000; 9: 78-82.
46. Brown J, Buckley D, Coulthard A et al. Magnetic resonance imaging screening in women at genetic risk of breast cancer: Imaging and analysis protocol for the UK multicentre study. UK MRI Breast Screening Study Advisory Group. Magn Reson Imaging 2000; 18: 765-776.
47. Warren RM, Pointon L, Thompson D et al. Reading protocol for dynamic contrast-enhanced MR images of the breast: Sensittvity and specificity analysis. Radiology 2005; 236: 779-788.
48. Liberman L. Breast cancer screening with MRI - what are the data for patients at high risk? N Engl J Med 2004; 351: 497-500.
49. Robson ME, Offit K. Breast MRI for women with hereditary cancer risk. J Am Med Assoc 2004; 292: 1368-1370.
50. Warner E, Causer PA. MRI surveillance for hereditary breast-cancer risk. Lancet 2005; 365: 1747-1749.
51. Lehman CD, Blume JD, Weatherall P et al. Screening women at high risk for breast cancer with mammography and magnetic resonance imaging. Cancer 2005; 103: 1898-1905.
52. Kuhl CK, Schrading S, Leutner CC et al. Mammography, breast ultrasound, and magnetic resonance imaging for surveillance of women at high familial risk for breast cancer. J Clin Oncol 2005; 23: 8469-8476.